These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26373212)

  • 1. Analysis of factors affecting time in therapeutic range control after warfarin administration.
    Kose E; Arai S; An T; Kikkawa A; Aoyama T; Matsumoto Y; Hayashi H
    Pharmazie; 2015 Jul; 70(7):494-8. PubMed ID: 26373212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
    Van Spall HG; Wallentin L; Yusuf S; Eikelboom JW; Nieuwlaat R; Yang S; Kabali C; Reilly PA; Ezekowitz MD; Connolly SJ
    Circulation; 2012 Nov; 126(19):2309-16. PubMed ID: 23027801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
    Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
    J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of a novel patient self-management program for warfarin therapy using venipuncture-acquired international normalized ratio monitoring.
    Simmons BJ; Jenner KM; Delate T; Clark NP; Kurz D; Witt DM
    Pharmacotherapy; 2012 Dec; 32(12):1078-84. PubMed ID: 23112110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink.
    Macedo AF; Bell J; McCarron C; Conroy R; Richardson J; Scowcroft A; Sunderland T; Rotheram N
    Thromb Res; 2015 Aug; 136(2):250-60. PubMed ID: 26073321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM).
    Sullivan RM; Zhang J; Zamba G; Lip GY; Olshansky B
    Am J Cardiol; 2012 Dec; 110(12):1799-802. PubMed ID: 22995971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients.
    Tomita H; Kadokami T; Momii H; Kawamura N; Yoshida M; Inou T; Fukuizumi Y; Usui M; Funakoshi K; Yamada S; Aomori T; Yamamoto K; Uno T; Ando S;
    Thromb Res; 2013 Nov; 132(5):537-42. PubMed ID: 24071466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia.
    Bernaitis N; Badrick T; Davey AK; Anoopkumar-Dukie S
    Intern Med J; 2016 Aug; 46(8):925-31. PubMed ID: 27040159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant management of atrial fibrillation: the influence of dosing algorithm and recall schedule on time in therapeutic range.
    Swarna Nantha Y
    Fam Pract; 2015 Oct; 32(5):514-9. PubMed ID: 26251026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.
    Han SY; Palmeri ST; Broderick SH; Hasselblad V; Rendall D; Stevens S; Tenaglia A; Velazquez E; Whellan D; Wagner G; Heitner JF
    J Electrocardiol; 2013; 46(1):45-50. PubMed ID: 23063241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation.
    Nelson WW; Choi JC; Vanderpoel J; Damaraju CV; Wildgoose P; Fields LE; Schein JR
    Am J Cardiol; 2013 Aug; 112(4):509-12. PubMed ID: 23800552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
    White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW
    Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
    Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.